Key facts
- It has raised $9.3M; the latest was Early Stage VC ($9.3M) in Oct 2025.
- Notable investors include Dylan Field, Solari Capital, Apollo Projects, Hydrazine Capital, Dimensional Fund Advisors — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Arcadia Medicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Arcadia Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Arcadia Medicine
Developer of psychoactive compound-based therapeutics designed for mental health treatment. The company's platform addresses conditions such as generalized anxiety disorder, major depressive disorder, and substance use disorder by utilizing a pharmacological model that evaluates receptor affinity, metabolic profiles, and safety data, enabling patients to access therapies with improved safety and efficacy profiles.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2020
- Employees
- 4
- Website
- arcadiamedicine.com/
- Ownership
- Privately Held (backing)
Arcadia Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arcadia Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arcadia Medicine in its N-PORT filings yet. We sweep new filings monthly.